Dolutegravir(DTG) | Integrase Antiviral Inhibitors

Despite several reverse transcriptase and protease inhibitors being used successfully from the mid-1990s onwards in the management of HIV-infected patients, it has only been in the last decade that the viral integrase enzyme has emerged as a primary alternative target to block HIV-1 replication. Because integration is a crucial step in the retrovirus replication machinery, the viral integrase enzyme has become an attractive molecule for the treatment of sub­jects infected with HIV-1.